Media headlines about Kindred Biosciences (NASDAQ:KIN) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kindred Biosciences earned a news impact score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.5563609055865 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on KIN. Zacks Investment Research raised shares of Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Thursday, August 3rd. Aegis began coverage on shares of Kindred Biosciences in a report on Friday, June 16th. They set a “buy” rating and a $10.50 price objective for the company. ValuEngine raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. FBR & Co reaffirmed a “buy” rating on shares of Kindred Biosciences in a report on Wednesday, May 31st. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $8.00 price objective on shares of Kindred Biosciences in a report on Monday, May 15th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Kindred Biosciences currently has an average rating of “Buy” and an average price target of $8.85.

Shares of Kindred Biosciences (NASDAQ KIN) traded down 0.68% during mid-day trading on Tuesday, hitting $7.30. 36,016 shares of the company were exchanged. The firm’s market capitalization is $170.16 million. Kindred Biosciences has a 12-month low of $3.86 and a 12-month high of $9.65. The company’s 50-day moving average price is $7.85 and its 200-day moving average price is $6.97.

In other Kindred Biosciences news, major shareholder Park West Asset Management Llc bought 15,311 shares of the firm’s stock in a transaction dated Thursday, June 8th. The stock was acquired at an average cost of $6.65 per share, for a total transaction of $101,818.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Richard Chin sold 13,000 shares of Kindred Biosciences stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $8.26, for a total value of $107,380.00. Following the sale, the insider now owns 2,297,546 shares of the company’s stock, valued at $18,977,729.96. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 770,387 shares of company stock valued at $5,660,987. 19.10% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Kindred Biosciences (KIN) Receiving Somewhat Favorable Media Coverage, Study Finds” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with's FREE daily email newsletter.